In this white paper, we explore the growing body of data that show how nonalcoholic fatty liver disease (NAFLD) is becoming recognized as a significant burden to patients, providers, and the overall healthcare system. One study concluded that the costs associated with the care for NAFLD were significantly higher than matched controls with similar metabolic profiles, even before the introduction of pharmacological treatments
FibroScan will be included in over 163 abstracts including 18 oral presentations that will evaluate utilization of the non-invasive FibroScan® tool across a variety of liver disease etiologies and practice settings
Given the shift to value-based medicine and the significant cost implications of NASH, the study explored which outcomes and quality measures KOLs would recommend for value-based contracting.
Researchers will present over 160 peer reviewed posters and oral presentations that include FibroScan during The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD)